This is especially important for individuals with absorption issues, such as those with gut inflammation or certain dietary restrictions
Manabe K, Kamihata H, Motohiro M, Senoo T, Yoshida S, Iwasaka T (2012) Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury
Concurrent medications theoretically could affect BPC-157 pharmacokinetics through alterations in renal clearance, peptidase activity, or tissue binding
Sold exclusively for in-vitro laboratory research
Safety across the full program was consistently favorable: adverse events, primarily mild headache and gastrointestinal symptoms, occurred at rates comparable to placebo, with no treatment-related discontinuations, no IGF-1 elevation, and no impact on glucose metabolism
If the deficiency is severe, remarkably, it can lead to permanent nerve damage